Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Aquestive Therapeutics ( (AQST) ) is now available.
Aquestive Therapeutics announced its second quarter 2025 financial results and business updates, highlighting the FDA’s acceptance of their New Drug Application for Anaphylm, a sublingual film epinephrine product. The company is preparing for a potential U.S. launch in 2026 and is also pursuing regulatory engagements in Canada and the EU. Aquestive aims to address unmet needs in emergency allergy treatment with Anaphylm, which offers advantages over existing epinephrine therapies. Financially, the company reported a net loss of $13.5 million for the second quarter of 2025, attributed to decreased revenues and increased expenses.
The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Spark’s Take on AQST Stock
According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.
The overall stock score is primarily influenced by the company’s challenging financial performance, characterized by declining revenues, negative profit margins, and high leverage. Although the technical analysis suggests positive momentum, the valuation remains unattractive due to ongoing losses. The earnings call provided some optimism with strategic progress for Anaphylm, but significant financial challenges persist.
To see Spark’s full report on AQST stock, click here.
More about Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on advancing medicines through innovative science and delivery technologies. The company specializes in developing non-invasive drug delivery systems, with a market focus on improving patient experiences and accessibility to treatments.
Average Trading Volume: 1,486,131
Technical Sentiment Signal: Strong Buy
Current Market Cap: $387.4M
For detailed information about AQST stock, go to TipRanks’ Stock Analysis page.